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The Psychiatric Genomics Consortium (PGC) is the largest
consortium in the history of psychiatry. This global effort is
dedicated to rapid progress andopen science, and in the past
decade it has delivered an increasing flow of new knowledge
about the fundamental basis of common psychiatric disor-
ders. The PGC has recently commenced a program of re-
search designed to deliver “actionable” findings—genomic
results that 1) reveal fundamental biology, 2) inform clinical
practice, and 3) deliver new therapeutic targets. The central
idea of the PGC is to convert the family history risk factor into
biologically, clinically, and therapeutically meaningful in-
sights. The emerging findings suggest that we are entering a
phase of accelerated genetic discovery for multiple psy-
chiatric disorders. These findings are likely to elucidate the
genetic portions of these truly complex traits, and this
knowledge can then bemined for its relevance for improved
therapeutics and its impact on psychiatric practice within a
precision medicine framework.
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Heredity is intimately related
to the history of psychiatry.
Clinical observations by early
physicians noted the tendency
of mental illnesses to run in
families. In the 20th century,
these anecdotes were system-
atically evaluated, and somewere confirmed in rigoroustwin,
family, and adoption genetic epidemiological studies. This
exceptional body of evidence provided a major etiological clue
for the field: common psychiatric disorders have a moderate to
strong tendency to run in families largely due to genetic in-
heritance (1, 2).
For instance, in 1946 Kallmann published an influential
twin study of schizophrenia in this journal (3). Kallmannwas
a psychiatrist and the fourth president of the American So-
ciety forHumanGenetics. Kallmann’s study of 691 twin pairs
was the largest in thefield for nearly four decades. Reanalysis
of these data (4) yielded an estimate of the heritability of
schizophrenia (91%) that was higher than estimates from
more recent national-scale studies (60%265%) (5, 6). Although
Kallmann’s speculation that schizophrenia was due to an au-
tosomal recessivemutation has been disproven, the concluding
line of his article remains exceptionally important, stating that
a genetic theory of schizophrenia is “equally compatible with
the psychiatric concept that
schizophrenia can be pre-
vented as well as cured.”
We now know that these
genetic effects are relatively
small and nondeterministic:
most people with a strong
family history are not themselves affected (as is also observed
for most complex biomedical diseases). Moreover, most psy-
chiatric disorders do not “breed true.” For example, the im-
mediate relatives of peoplewith schizophrenia have increased
risks not only for schizophrenia but also for multiple other
conditions (e.g., bipolar disorder, major depressive disorder,
and autism). The diverse clinical manifestations and variable
course observed for many common psychiatric disorders are
consistent with complex and relatively small genetic effects.
For adult-onset common psychiatric disorders in particular,
development is often within normal limits, although there is
often some impairment of higher components of cognition.
In the last decade it has become technically and economi-
cally feasible to interrogate the genome directly with increas-
ing resolution and completeness. Instead of indirectly studying
the heredity of psychiatric disorders (e.g., through studies of
pedigrees, twins, or adoptees), we can now evaluate the ge-
nomes of case and control subjects at several levels of precision
the search space. We quickly learned that optimistic as-
sumptions of large genetic effect sizes for these disorders
were incorrect. The initial GWAS for psychiatric disorders
had sample sizes of approximately 1,000 cases, enabling
excellent power to detect a genotypic relative risk $2.5.
However, these effectswerenot found for schizophrenia (16),
bipolar disorder (17), major depressive disorder (18), or at-
tention deficit hyperactivity disorder (ADHD) (19). Figure 1A
also shows the 90% power curve for the most successful
GWAS of any psychiatric disorder (37,000 schizophrenia
cases) (15), and only two of 128 independent loci had ge-
notypic relative risks $1.2. Compellingly, we can now
demonstrate that common genetic variants with genotypic
relative risks above ∼1.24 for schizophrenia can be ex-
cluded with about 100% power.
Genetic effects that are common and large are unusual
for human diseases and traits studied by means of GWAS
(Figure 1B). They are occasionally found for less complex
conditions that can be assessed with exceptional precision
(e.g., infectious diseases, rare adverse drug reactions, and eye
diseases). To our knowledge, the largest common genetic
variant associations observed to date in psychiatry are for
alcoholism in people of East Asian ancestry (genotypic rel-
ative risk, ∼6.2) (20) and clozapine-induced agranulocytosis
(genotypic relative risk, ∼5.3) (21).
GENETIC ARCHITECTURE ANDMODELS OF DISEASE
Elucidation of the genetic architecture underlying these
disorders is the major goal of the PGC. How many suscep-
tibility or protective variants are there? What are their fre-
quencies and effect sizes?Howdo they exert their effects?Do
these variants interact with one another or with environ-
mental risk factors? Crucially for biological understanding,
which genes are affected by these variants?
It is heuristically useful to consider the “bookends.” The
extreme models are that psychiatric disorders are caused by
1) the cumulative impact of hundreds or thousands of com-
mon genetic variants each of small effect (common disease/
common variantmodel) or 2)many different gene-disrupting
variants of strong effect (multiple rare variant model). In the
lattermodel, every personwith a serious psychiatric disorder
would have a strong effect variant, and thesewould cluster in
a set of genes important to brain development and function.
These models were passionately debated. Some authors
expressedprofoundhope that themultiple rarevariantmodel
was broadly explanatory (22–24). Others favored a common
disease/common variant model, arguing that psychiatric
phenotypes are comparatively subtle. Most investigators
were agnostic. The PGCwished to design studies that would
be informative whatever the underlying model (9).
INITIAL STRATEGY
A consistent lesson from the history of psychiatric genomics
was that these are very hard problems: any search is going to
quickly and inexpensively. Indeed, heritability itself can be 
assessed directly from genome-wide genetic data (7, 8).
By carefully evaluating the successes and failures of psy-
chiatric genetics in the past three decades, we now have a solid 
fixonhowtodissect the“family history risk factor” into farmore 
precise and mechanistic components. We can identify genetic 
variants that contribute to risk and are moving toward un-
derstanding the mechanisms by which they act. The field has 
learnedanenormous amountandispoisedto make fundamental 
advances that could profoundly improve understanding.
This review provides an update on what we have learned 
and puts forth an agenda for the next 5 years. A key lesson was 
the need for a global community effort in psychiatric genetics 
because the required sample sizes are far beyond the reach of 
any single group. To enable these studies, in 2007we formed the 
Psychiatric Genomics Consortium (PGC) (http://www.med. 
unc.edu/pgc). Our overarching goal is to deliver actionable 
knowledge, i.e., genetic findings whose biological implications 
can be used to improve diagnosis,develop rational therapeutics, 
and craft mechanistic approaches to primary prevention.
GETTING UP TO SPEED IN GENETICS
In 2009, the PGC published three foundational articles regarding 
genome-wide association studies (GWAS) (9–11). GWAS is a 
genomic study design that focuses on the impact of common 
genetic variation in almost all genes in the human genome. The 
initial PGC articles covered the core concepts, history, rationale, 
genomic assays, statistical analysis, interpretative framework, 
and importance of cross-disorder studies in psychiatry. Full 
background of the terminology, core concepts, and strategy of 
GWAS can be found in these articles. Basic terms are defined in 
TableS1inthedatasupplementaccompanyingtheonlineversion 
of this article, and a “primer” has been published previously (12).
CLARITY IN RETROSPECT
A key unknown was genetic architecture, particularly the 
sizes of the underlying genetic effects. A decade ago these 
were unknown and subject to considerable speculation, with 
hypotheses suggesting that genetic discovery for psychiatric 
disorders would be anywhere from highly tractable to im-
possible. If the genetic effects were few, common, and large, 
relatively modest sample sizes would be sufficient. A few early 
studies hinted that small samples might suffice (e.g., studies of 
the effects of APOE on Alzheimer’s disease [13] or CFH on age-
related macular degeneration [14]), and these may have led to 
expectations that gene discovery would be straightforward.
The power calculations are not difficult: for a given 
number of case and control subjects (plus assumptions of 
allele frequency, genetic model, significance threshold, and 
power), it is easy to compute the minimum detectable ge-
notypic relative risk. For example, Figure 1A shows the 90%
power curve for a GWAS of 1,000 cases and 1,000 controls.
Like most investigators in human complex disease ge-
nomics, we had limited data to allow us to narrow bounds on





























A. Statistical power of GWAS (in theory)a
B. Odds ratios and allele frequencies from published GWASb
Allele Frequency in Control Subjects (log10)

































a Upper curve (blue) shows minimum detectable genotypic relative risks for common variants for 1,000 cases and 1,000 control subjects (90% power,
additive model, lifetime risk 0.01, a=531028). Lower curve (red) shows 90% power for the Psychiatric Genomics Consortium (PGC) 2014 schizophre-
nia article (15) (37,000 cases and 113,000 control subjects, additive model, lifetime morbid risk 0.01, a=531028). Black dots show the top 10 loci in
the PGC schizophrenia report. These loci are highly significant with p values ranging from 1.7310213 to 3.8310232.
b From the National Human Genome Research Institute (NHGRI) and European Bioinformatics Institute (EBI) catalog (accessed Jan. 27, 2017), which
contains 2,308 GWAS papers published betweenMarch 2005 and July 2016. There are 9,485 SNP–trait associations (p#13128) including 7,487 SNPS
and 870 traits. Dots show odds ratios (ORs) and allele frequencies (ORs transformed to be.1, frequencies transformed to be 0–0.50). Contours show
densest areas of the plot. Red horizontal lines show 50th (OR=1.22) and 90th (OR=1.95) percentiles for ORs: most associations are subtle. Of
62 associations with OR .5, most are for infectious disease (N=31; e.g., influenza susceptibility), pharmacogenomic relationships (N=13; e.g., rare
adversedrug reactions suchasflucloxacillin-induced liver injury), eyedisease (N=4;e.g., glaucoma),orpigmentation (N=2;e.g., blueversusbrowneyes).
Onlya fewdiseaseshaveatypically largeORs (e.g., celiacdisease,melanoma,membranousnephropathy,myasthenia gravis, ovariancancer, Parkinson’s
disease, progressive supranuclear palsy, thyrotoxic hypokalemic periodic paralysis, and type 1 diabetes). The only psychiatric finding was alcohol
consumption and ALDH2 in individuals of East Asian ancestry.
variants of strong effect (e.g., intellectual disability or early-
onset Alzheimer’s disease), there is always a contribution of
common variation. Rare variant studies have proven more
difficult than anticipated, because to confidently identify rare
variants of strong effect in typical clinical samples requires
very large sample sizes, perhaps as many as around 100,000
cases (38).Theprotein-codingpartsof thegenomeare replete
with inconsequential variation, and current ways to predict
functional consequences are imprecise (39). There is a lot of
noise, and the signal is sparser and weaker than anticipated.
Figure 3C showscurrent sample sizes andnotablefindings
for the PGCworking groups. Schizophrenia has accumulated
the most data for both common and rare variation. Figure 2B
shows significant results fromGWAS, copy number variation
(CNV), and exome sequencing studies (15, 36, 37). Most
findings are for common variation. Multiple rare CNVs have
been implicated;most aremultigenic, and all increase risk for
several psychiatric disorders and neurological diseases (36).
SETD1A is the only gene implicated to date by whole-exome
sequencing studies (37), but other such studies have only
found hints of biological pathways by focusing on extremely
rare variation (40, 41). It was widely anticipated that exon
variation in the 0.005 to 0.01 allele frequency range would
be readily found, but this has not been observed (42), and
a recent study of height required over 700,000 subjects to
identify loci in this range (43). In a direct comparison,
common variation had 14–28 times more impact on risk for
schizophrenia than rare CNVs or rare exonic variation (44).
Another major finding has been the repeated empirical
documentation of important genetic overlap (particularly
common variation) among most or all adult- and childhood-
onset psychiatric disorders (26, 27). It is clear that psychiatric
nosology has not “carved nature at the joints.”Moreover, the
commonvariantgenetic architectureofmanydisordersblends
intonormalphenomena.Forexample, therearesizablegenetic
correlations of major depressive disorder with personality
traits like neuroticism and readily assessed depressive symp-
tom measures. Other findings suggest that reconceptualiza-
tions may be needed. For example, anorexia nervosa had a
significant positive genetic correlation with schizophrenia,
significant negative genetic correlationswith bodymass index
and unfavorable metabolic measures, and significant positive
genetic correlations with favorable metabolic factors. This
pattern of findings suggests that the roots of anorexia nervosa
may be not only psychiatric, but also metabolic, in origin.
The PGCwork group on depression recently completed a
report that identified 44 genetic loci for major depressive
disorder (45).Thiswork is notablebecauseof the compressed
time scale (2 months from final results to submission) as well
as its demonstration of what the findings can tell us. The
individual loci yielded multiple strong candidate genes (e.g.,
NEGR1, RBFOX1, and SOX5). The findings were associated
with clinical features of depression (e.g., earlier age at onset
and recurrent and more severe forms of depression). Gene
expression patterns in the prefrontal and anterior cingulate
cortexmost closelymatched the geneticfindings (these brain
be far more difficult than anticipated. Although we were 
hopeful that the initial GWAS might deliver insights, we 
created the PGC in order to hedge our bets; we needed a 
framework to aggregate data across studies with exceptional 
care and rigor if we were to progress. A critical step was 
to convince all groups that sharing individual data was 
essential—this is a foundational principle of the PGC and 
allows optimal quality control and analysis.
Moreover, to ensure progress, an “open science” per-
spective was required. Genome-wide summary statistics of 
all PGC analyses are available for widespread use (http://
www.med.unc.edu/pgc), and the vast majority of PGC ge-
notype data that can be deposited are available to qualified 
researchers in a controlled-access repository. We recently 
have made available a list of the top loci from PGC analyses 
(both published and in preparation).
These early strategic decisions proved important, as re-
sults from the first wave of psychiatric GWAS, circa 2008, 
were unimpressive. Although we were careful not to hype 
GWAS (9, 10), some prominent commentators voiced strong 
doubts about its value—even though careful review of the 
early results showed unequivocal indications of genetic ef-
fects. The first-wave studies were simply underpowered, and 
combining studies to increase power was logical. Never-
theless, we persisted, and a 2012 letter signed by 96 psychi-
atric genetics investigators (“Don’t give up on GWAS”) 
anticipated the utility of GWAS should sample sizes in-
crease (25).
To date, the PGC has published 24 main articles and 
51 secondary analysis articles (see Table S2 in the online data 
supplement). At least 141 additional papers have made use of 
PGC results. Many PGC papers are highly cited, but chief 
among them is the 2014 schizophrenia report (15), which 
ranks among the most highly cited articles in 2014. The PGC is 
among the leading genomic consortia worldwide for open 
science and data sharing. These successes are a testimony to 
the fact-based strategy and persistence of the PGC.
AN UPDATE
What have we learned? We now have a sizable body of 
empirical results relevant to the “common versus rare vari-
ant” debate. All common psychiatric disorders with suffi-
ciently large samples have a predominant common disease/
common variant contribution (26–28). Indeed, this is widely 
seen across human complex diseases, such as type 2 diabetes 
mellitus (29), and anthropometric traits, such as height (30) 
and body mass (31). Demonstrating a major role of common 
genetic variation in risk for human complex traits (including 
psychiatric disorders) is so widely and consistently docu-
mented that it is no longer particularly newsworthy.
There is a variable contribution of rare variation of strong 
effect. This tends to be larger for early-onset, severe disorders 
and lesser for disorders with normal-range developmental 
trajectories and adult onset (Figure 2A). However, even for 
psychiatric disorders with many proven examples of rare
factor—have never been easy. However, by incorporating
empirical results, a data-driven and logical way forward has
emerged, and it is likely that these effortswill continue to yield
importantnewknowledge.Manygroups areactive in this area,
but thePGChasemergedas thekeyumbrellaorganizationfora
large portion of this work. A basic description of the PGC and
its core principles is given in Figure 3A. Key technical aspects
include its dedication to rigorousmethodologies and its stance
as a “mega-analysis” consortium with PGC members sharing
individual-level genotype and phenotype data.
With continued support from the National Institute on
Mental Health (NIMH) (and new support from the National
Institute on Drug Abuse), the PGC recently initiated a pro-
gram of research designed to deliver “actionable” findings,
genomic results that 1) reveal the fundamental biology, 2)
inform clinical practice, and 3) deliver new therapeutic
targets. This is the central idea of the PGC: to convert the













































A. Genetic causes of severe psychiatric disordersa















aGenetic causes of severe intellectual disability (32), autism spectrum disorder (33, 34), and schizophrenia (35) include copy number variants (CNVs),
inherited known recessives, and single-nucleotide variants (SNVs). For severe intellectual disability, most SNVs and CNVs are de novo. The “Unknown”
grouping includes common variation, undiscovered rare genetic causes, phenocopies, and causation due to nongenetic effects.
bOdds ratios are transformed to be .1, and frequencies are transformed to be #0.5. The dots on the lower right (cyan) show common variant
associations for schizophrenia (p,131028) (15).Opendiamonds (red) showcopynumber variation associatedwith schizophrenia (36). Thefilled square
(green) shows the lone variant identified using whole exome sequencing (37).
regions also show MRI differences between patients with 
major depression and control subjects). Genes that are targets 
of antidepressant medications were strongly enriched for  
depression association signals (p=8.5310210), suggesting 
pharmacotherapeutic relevance. The genetic bases of lower 
educational attainment and higher body mass were putatively 
causal for major depressive disorder, whereas depression and 
schizophrenia reflected a partly shared biological etiology.
This is an evolving area with regular increases in confident 
knowledge. To encourage rapid dissemination of results, the 
PGC regularly compiles and shares a list of the strongest 
findings for the disorders it studies.
A CONSORTIUM AGENDA
Attempts to understand the genetic basis of psychiatric 
disorders—to untangle and concretize the family history risk
Aims of Work on Common Genetic Variation
Aim 1. Aim 1 is the core business of the PGC: to conduct
progressively larger GWAS mega-analyses and systematic
cross-disorderanalyses (46).Figure4Adepicts theprogression
FIGURE 3. Background, Current Projects, and Findings to Date of the Psychiatric Genomics Consortium (PGC)
A. BACKGROUND
General Information
•  The PGC has been in continuous existence from 2007 to the pres-
ent.
•  The international membership includes over 800 scientists from
40 countries.
•  The nine PGC working groups study attention defi cit hyperactivity
disorder, autism, bipolar disorder, eating disorders, major depres-
sive disorder, obsessive-compulsive disorder/Tourette syndrome,
posttraumatic stress disorder, schizophrenia, and substance use
disorders. Provisional groups for anxiety disorders and Alzheimer’s 
disease were added in 2016.
•  Current goals are to obtain genome-wide association data on
100,000 cases for each disorder.
•  The PGC includes groups focused on cross-disorder analysis,
copy number variation, statistical analysis, and pathway analysis.
•  The PGC has published 24 main papers and 51 secondary analysis
papers (see Table S2 in the data supplement accompanying the
online version of this article). At least 141 papers have made use of 
PGC results.
PGC Core Principles
•  Given the human, medical, and societal impact of psychiatric
disorders, the PGC is passionate about rapid progress, and it is a
world leader in data and results sharing.
•  The PGC is characterized by open, inclusive, participatory, and
democratic science.
•  Core PGC activities are commercially “pre-competitive”: identify-
ing the genomic results is a public good and part of the fundamen-
tal characterization of these psychiatric disorders.
•  The PGC is committed to producing robust, replicable, and se-
cure fi ndings. Its work is based on rigorous methodology, a strong 
empirical focus, and healthy questioning of prior knowledge and
assumptions.
•  The PGC has a “mega-analysis” framework: members share raw
genotype data so that all samples can be processed using a uni-
form quality control, imputation, and analysis pipeline.
C. FINDINGS TO DATE
a
PGC Group Cases Hits Twin h2 SNP h2 Notable Genetic Correlations
Schizophrenia 60,995 155 81% 45% Bipolar disorder
Major depressive disorder 130,664 44 30%–40% 8.9% Worse sleep, greater body mass, and lower educational attainment
Bipolar disorder 20,352 19 80% 21% Schizophrenia
Attention defi cit hyperactivity 
disorder
20,183 12 70%–80% 22% Highest educational attainment
Autism spectrum disorder 18,381 3 75% 12% Self-reported well-being
Anorexia nervosa 3,495 1 56% ~20% Lower body mass and metabolic traits
Substance use disorders 12,798 1 50% ~8% Smoking, alcohol consumption
Tourette syndrome 4,232 1 60%–80% 58% OCD
Obsessive-compulsive disorder 2,688 0 45%–65% 37% Tourette syndrome
Posttraumatic stress disorder 5,131 0 30%–40% 5%–35% Schizophrenia
a  Hits: independent associations reaching genome-wide signifi cance. Twin h2: heritability estimated from twin studies. SNP h2: heritability estimated 
from results of genome-wide association studies (GWAS).
B. CURRENT PROJECTS
Common Genetic Variation: Continue and Expand PGC’s Ongoing 
Work to Increase Knowledge
1.  GWAS. (a) The core business of the PGC: progressively larger
GWAS mega-analyses for all disorders studied by the PGC. (b)
Systematic cross-disorder analyses. (c) Pathway analyses to clar-
ify biological implications. Critically, we have engaged academic
and industry experts in psychopharmacology to maximize thera-
peutic implications of the fi ndings.
2.  Genetic risk scores. (a) Development: use data from large longi-
tudinal cohorts to evaluate the developmental eff ects of genetic
risk scores. (b) Clinical symptoms: analyze relationship between
clinical descriptors and genetic risk scores to understand clini-
cal relevance. (c) G×E: analyze interactions between genetic risk
scores and environment.
3.  Brainstorm initiative. Apply novel statistical methods to GWAS
results to estimate pairwise genetic correlations among all PGC
disorders and with all obtainable CNS-relevant diseases/quanti-
tative traits (e.g., epilepsy, neuroimaging, personality, IQ) to de-
velop a comprehensive portrait of genetic infl uences across a
broad set of brain phenotypes.
Rare Variation: Enhance Discovery of Alleles With Larger Eff ects 
on Risk
4.  Copy number variants (CNVs). Analyze rare CNVs in all PGC disor-
ders via high-quality mega-analyses, and perform cross-disorder 
analyses to reveal pleiotropic genetic eff ects.
5.  Sequencing. Characterize the full spectrum of genetic variation
for schizophrenia (especially rare variants of strong eff ect) in re-
gions implicated in Aim 1. Inexpensively sequence coding and
regulatory regions of ~200 candidate genes in 20,000 indepen-
dent subjects.
6.  Pedigree sequencing. The large network of PGC clinicians has
identifi ed unusual pedigrees densely aff ected with psychiatric
disorders. Systematically evaluate ~100 pedigrees for CNVs, high
genetic risk scores, and whole-genome sequencing to enable
searches for rare variants of strong eff ect.
family history risk factor into biologically, clinically, and 
therapeutically meaningful insights. This program of re-
search has six aims, three focused on common variation and 
three on rare variation (Figure 3B).
Aim2.Aim2concerns the analysis of genetic risk scores. For a
complex disease or trait, the genetic risk score is a single,
normally distributed variable that captures the cumulative
effect of risk alleles inherited by an individual (e.g., for
schizophrenia, bipolar disorder, or body mass index). Com-
puting a genetic risk score requires a training set (i.e., GWAS
results) and genome-wide genotypes for independent test
subjects (e.g., a population cohort or participants in a clinical
trial). The PGC has made training sets publicly available for
multiple disorders. This allows researchers to compute ge-
netic risk scores for whatever use they deem appropriate.
These scores are not yet sufficiently discriminating to be
useful clinically (15) but are among the first demonstrably
valid biomarkers for psychiatric disorders. Genetic risk
scores derived from PGC results have been widely used
in psychiatric research for generating patient strata, ex-
ploring diagnostic boundaries, identifying cognitive and
behavioral correlates of genetic risk that predate clinical
disorders, and evaluating the validity of putative cognitive
or imaging phenotypes (51). Many social scientists have
embraced the approach, seeing opportunities to study how
genetic factors interact with the social environment (e.g.,
socioeconomic status) to influence health and broader
outcomes (52).
ThePGCwill systematically evaluate genetic risk scores in
three contexts: 1) development—use data from large longi-
tudinal cohorts to evaluate the developmental effects of
genetic risk scores; 2) clinical—analyze the relationship be-
tween clinical descriptors/symptoms (e.g., early versus late
onset, more severe versus milder, or unremitting versus
episodic illness) and the genetic risk score to understand
clinical relevance; and 3) environment—analyze interactions
betweenthegenetic risk scoreandenvironmental variables in
epidemiological samples.
Aim 3. Aim 3 will use GWAS results to estimate pairwise
genetic correlations among all PGC disorders with all ob-
tainable CNS-relevant diseases and quantitative traits (e.g.,
epilepsy, neuroimaging, personality, and cognition). We will
developacomprehensiveportrait of genetic influences across
a broad set of brain phenotypes with the intention of im-
proving nosology.
Past epidemiological studies have documented the ex-
tensive comorbidities of psychiatric disorders at the phe-
notype level. Due to limitations inherent to observational
studies, understanding whether a phenotypic correlation is
potentially causal or if it results from reverse causation or
confounding is generally difficult or impossible. Genetic
studies now offer complementary strategies. We can readily
assesswhether a phenotypic association betweenpsychiatric
disorders or between a psychiatric disorder and a risk factor
is mirrored by a common variant genetic correlation. This
can be done using GWAS summary statistics. If the gene-
tic studies are sufficiently large, it is also possible to apply
Mendelian randomization to evaluate the potential causality
of the association (53).
of sample sizes with time. Our goal is for each of the nine 
disorder working groups to obtain GWAS data on 100,000 
cases. More information on case definitions can be found in 
Table S3 in the online data supplement.
Figure 4B encapsulates the experience with sample size 
and numbers of significant associations. Some disorders have 
a fortuitous architecture; for instance, inflammatory bowel 
disease obtained a considerable number of findings with 
relatively small samples. For most other complex traits, the 
path is slower but with sufficient samples discovery becomes 
linear. Figure 4C shows an idealized model of the sigmoid-like 
discovery process from “dead zone” to asymptote. We suggest 
that the goal is to get to a “good enough” point, where most 
genes are identified at least once and the majority of genes in 
salient biological processes are highlighted. This can provide 
an etiologic scaffold for studies that use other methods to 
identify interacting partners in gene networks and pathways 
that underlie pathogenesis. There may be on the order of 
1,000 genes involved in schizophrenia (47) (for comparison, 
approximately 13,000 genes are expressed in the brain and 
about 2,000 at the synapse). Most of the nine PGC disorder 
working groups have identified at least one genome-wide 
significant association, several are accumulating moderate 
numbers of loci, and schizophrenia and major depression 
appear to be in the linear phase (Figure 3C).
The PGC has extended its initial efforts in three ways. 
First, we added four new and highly motivated groups (on 
eating disorders, obsessive-compulsive disorder/Tourette 
syndrome, posttraumatic stress disorder [PTSD], and sub-
stance use disorders). Provisional groups for anxiety disor-
ders and Alzheimer’s disease have been formed. Second, we 
hope to markedly increase inclusion of non-European sam-
ples (see Figure S1 in the online data supplement). For ex-
ample, the PGC is now completing a report based on over 
12,000 schizophrenia cases from East Asia. The PTSD and 
substance use disorders groups are studying increasingly 
larger samples of African Americans. The Stanley Center of 
the Broad Institute has launched major sample collection 
efforts for multiple severe psychiatric disorders in Africa, 
South America, and Asia.
This work is crucial for generalizability. Although it is 
likely that most (but not all) associations will be observed 
across the world, there will also be population differences, 
and it is clear that the application of genetic risk scores 
globally (see next paragraph) will require risk allele weights 
derived from the major ancestral populations. Finally, the PGC 
has engaged academic and industry experts to understand the 
therapeutic salience of the findings (48). Indeed, the empirical 
targets of antipsychotic medications are markedly enriched for 
the results of schizophrenia GWAS, and this enrichment be-
came clearer with increasing sample sizes, as has the potential 
pharmacological relevance of calcium channels for psychiatry 
(49). The design of rational therapeutics has been an elusive 
goal for psychiatric indications, and improved genomic 
knowledge is a precompetitive activity that can make novel 
drug discovery more efficient (50).






































































































A. Numbers of cases for GWAS analysesa
B. Relation between numbers of cases and genome-wide
significant SNPs in GWASb
C. Hypothetical relation between numbers of cases and genome-wide 
significant associations for a human complex disease or traitc
a For the original five PGC disorders (ADHD to schizophrenia), the three bars represent the numbers of cases in the initial reports (PGC1), the next round
of papers (PGC2), and the projected numbers by 2019 (PGC3). For the four disorders added in 2013 (eating disorders to substance use disorders), the
PGC2 and projected PGC3 numbers are shown.
b Inflammatory bowel disease has an exceptional genetic architecture and excellent clinical diagnostic specificity,whichenabled considerable discovery
with relatively smaller numbers of cases. Schizophrenia, height, and bipolar disorder follow more typical and approximately similar discovery paths.
c There is an initial dead zone whose length depends on howmany cases are accrued and the largest effect size. This is followed by an inflection point
where the significant associations begin to accumulate and then a linear phase. Complexities arising from the true nature of the initially unknown genetic
architecture could change the form of this curve in important ways.
using comprehensive genomic assays (karyotyping, identity
by descent, CNVs, whole genome sequencing, and genetic
risk score) combined with a rigorous statistical framework.
However, a pedigree very dense with psychiatric disorders
can occur because a rare variant of strong effect is segregating
in that pedigree or because that pedigree has an unusually
high number of common variants of small effect (see refer-
ence 55 for an example).
Actionability
Among the aims related to common variants, aim 1 is of bi-
ological, clinical, and therapeutic relevance. Aims 2 and 3 are
important clinicallyand fornosology.Of the rare variant aims,
all are important biologically and therapeutically (given their
potential to identify single genes whose mutational disrup-
tion carries high risk).
ISSUES IN THE PROCESS OF BEING SOLVED
Empirical results from psychiatric genomics have begun to
answer many fundamental questions. We point to two major
unresolved issues. First, a crucial issue is pinpointing the
biological implications of GWAS results. What precise
mechanistic hypotheses arise from the findings? If a GWAS
“associates” a psychiatric disorder with a specific genomic
region, what genes should neuroscientists and molecular
biologists study in order to delvemore deeply into the basis of
a disorder? This is crucial for downstream experimentation,
as studying one gene in detail can easily consume several
person-years and hundreds of thousands of dollars.
Making connections from DNA sequence variation to a
cellularmechanism is sometimes straightforward.This is one
reason researchers like to exploit rare exon variants (aims
5 and 6), as the connection to a gene is usually direct and can
be logically evaluated with some confidence. Occasionally,
common variant findings can be directly implicated; for
example, the PGC major depression study found two
separate associations on opposite sides of the same gene
(RBFOX1) (45).
However, such findings are unusual for many common
psychiatric disorders (Figure 2), and connecting the nu-
merous common variant association signals to genes can be
challenging. Figure 5 illustrates typical patterns of results.
Figure 5A shows the CACNA1C intronic association for
schizophrenia; a subsequent study suggested that these
variants interact with a regulatory element for CACNA1C
(56). Figure 5B depicts the region surrounding DRD2
(encoding akey target of antipsychotics). This associationhas
been functionally connected to DRD2 via DNA-DNA regu-
latory loops (57). Figure 5C shows a multigenic region—the
association region covers many brain-expressed genes as-
sociated with multiple human traits. Figure 5D depicts a
region associatedwith schizophrenia but far fromany known
protein-coding gene.
These are typical for GWAS results. Although localization
is imprecise, the associated genomic regions are clearly
For example, a recent PGC study reported sizable positive 
genetic correlations between major depressive disorder and 
multiple measures of body mass (45). We investigated the 
association by using bidirectional Mendelian randomization 
and found evidence suggesting a potential genetic causal 
effect of body mass on risk for depression but not the reverse. 
These results provide hypotheses for more detailed pro-
spective studies, and the underlying mechanisms are likely to 
be more complex.
We will operationalize similar analyses for other disorders 
(e.g., autism with/without intellectual disability, bipolar 
disorder with/without psychosis or with/without lithium 
response). Given sex differences in disease prevalence for 
many disorders, analyses of genetic correlations by sex will be 
conducted as well. In addition, many of these disorders have 
significant genetic correlations with cognition, personality, 
and body mass. Are these genetic correlations putatively 
causal or due to some other process (confounding or bias)?
Differences between disorders will be investigated—for 
example, body mass has a positive genetic correlation with 
major depression but a negative genetic correlation with 
anorexia nervosa (54).
Aims of Work on Rare Genetic Variation
Aim 4. Aim 4 will continue the PGC’s CNV efforts (36). The 
PGC CNV group has created a pipeline to determine the 
presence or absence of CNVs from the initial intensity files by 
using multiple algorithms followed by careful quality control 
and analysis. The initial schizophrenia paper has been 
published, and this group is now working on bipolar disorder, 
ADHD, and PTSD and will include more groups with time.
Aim 5. Aim 5 is a “cheap-seq” aim. We will conduct in-
expensive (approximately $50/subject) schizophrenia-
focused sequencing of 200 genes in 20,000 subjects. Genes 
will be selected based on all available sequencing results. For 
200 genes, we will increase power far more cost-effectively 
than with whole-exome (10 times cheaper) or whole-genome 
(25 times cheaper) sequencing in the same time frame. We 
propose an efficient and affordable way to markedly increase 
sample sizes for the most promising loci in a new sample of 
20,000 subjects.
Aim 6. Aim 6 will systematically evaluate approximately 
100 large pedigrees to search for genetic variants of large 
effect. We have engaged the large network of PGC clinicians 
in this task. Most experienced clinicians have encountered 
unusual pedigrees with high concentrations of severe psy-
chiatric disorders. For example, one pedigree has more than 
100 individuals with a severe psychiatric disorder, and eight 
pedigrees have 20 or more affected individuals. Other ped-
igrees are from genetic isolates in which marriage between 
relatively close relatives is common. Still other pedigrees 
have extensive comorbidity with intellectual disability and 
epilepsy. No one has systematically and comprehensively 
evaluated a large collection of densely affected pedigrees
consortium (61) to conduct an array of functional genomic
assays on brain samples from people with severe psychiatric
disorders to enable this work. We anticipate considerable
progress in this area in the near future.
Second, as discussed above, the genetic basis of most
psychiatric disorders shows fundamental connections. For
example, the common variant genetic basis of major
FIGURE 5. Examples of Genomic Regions Significantly Associated With Schizophreniaa
a Examples of genome-wide significant regions for schizophrenia with tracks showing the location (hg19), genes in the region, GWAS results from the
literature, and the schizophrenia results (one green vertical bar per SNP, height corresponds to –log10(p value) with 7.3 equivalent to 5310
28.
informative as they implicate salient biological pathways 
(58), specific genomic features (59), and targets of common 
psychiatric medications (45, 49). Connecting most or all of 
the findings to specific genes requires additional data based 
on the function of the human brain, e.g., brain gene expres-
sion in brain regions (60), DNA-DNA looping (57), and 
epigenomics (61). NIMH has funded the PsychENCODE
seen not only in the genome-wide significant loci that we have
discovered, but also in the many phenotypes that have been
associated with PGC genetic risk score in both clinical and
population samples. The second step, under way now, is
detailed characterization of genetically informative subsets
of cases (e.g., aim 2). In addition, some PGCworking groups
(e.g., substance use disorders) are currently analyzing quan-
titative phenotypes.
CONCLUSIONS
ThePGC is the largest andmost systematic genomics effort in
the history of psychiatry. In the next 5 years, we propose to
markedly scale up ourwork. By tackling nature as it is andnot
as we might want it to be, we hope to provide considerable
new knowledge about the fundamental basis of psychiatric
disorders. Our long-standing commitment to global collab-
oration, open science, and rapid progress means that we will
make our results and tools available in a timely manner.
Predictionof the future is alwayshazardous, butgiven thatwe
finally have a minimally adequate toolkit for genomics, it is
possible thatwe are entering a golden age of research into the
fundamental basis of severe mental illness.
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depressive disorder overlaps significantly with those for 
anxiety disorders, autism, ADHD, schizophrenia, bipolar 
disorder, smoking behavior, and anorexia nervosa (45). 
Moreover, the presence or absence of some clinical disorders 
(major depression, autism, and ADHD) shows strong genetic 
overlap with the analogous symptoms in general population 
samples. Further, the common genetic basis of many psy-
chiatric disorders is often strongly correlated with that of 
putative subphenotypes (also known as endophenotypes or 
component phenotypes). For example, the common variant 
genetic basis of major depression is correlated with that for 
worse sleep, higher neuroticism, and greater body mass in 
people without major depression (45). These results strongly 
suggest that our diagnostic categories do not define patho-
physiological entities. The resolution of these issues will 
address major unanswered questions: From a genetic per-
spective, what are these disorders? How are they similar and 
how are they different?
COMMON COMPLAINTS
Briefly, there are three common complaints about the work of 
the PGC. First, “The results don’t matter”—the readouts are 
broad and the effect sizes of individual associated loci are 
small. In fact, as discussed above, the results are delivering 
increasingly useful and targeted knowledge (discussed above 
in the section on aim 1) (48, 49, 58). The small effect sizes do 
not constrain the potential utility of targeting the identified 
genes or pathways—drugs targeting those pathways can have 
major effects. Small effects can identify “druggable” targets; 
the canonical example of this is the identification by GWAS of 
common genetic variation of small effect for multiple choles-
terolmeasures in agene(HMGCR)whose proteinis the targetof 
a class of cholesterol-lowering medications (50). Pharmaceu-
tical companies are now following this area closely as genomic 
data are increasingly crucial to drug development (50).
Second, “What about unaccounted heritability (h2)?” 
Heritability estimated from genome-wide single nucleotide 
polymorphism data (SNP-h2) depends on technical issues 
and especially sample size. The comparator is estimated from 
imprecise twin or family data (twin-h2 or pedigree-h2). 
“Unaccounted h2” refers to the difference between these 
estimates and attempts to reconcile fundamentally different 
entities. Still, when the genomic study is sufficiently large 
(as with schizophrenia), SNP-h2 is around half of the pedigree-
h2. A point often missed, however, is that explaining h2 is a 
minor goal. The main goals of the PGC are to gain biological, 
clinical, and therapeutic insights, which can arise regardless of 
the magnitude of heritability accounted for.
Third, because most PGC analyses are based on cate-
gorical, case versus control analyses, “PGC cases lack clinical 
depth.” This was by intention: over 10 years ago (47), some of us 
reasoned that fast phenotype characterization that led to af-
fordably large sample sizes was the logical first step (as opposed 
to large numbers of phenotypes on small numbers of subjects). 
This was always the first step. The success of this strategy is
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